Trial · NCT04309877
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in depressed mood from baseline | At baseline and then at 1, 1.5, 2, 3, 4, 5, and 6 hours after LPS (or saline) administration | Short Form of the Profile of Mood States (POMS-SF) Depression Subscale with higher scores indicating more severe depressed mood (range 0-32) |
| Secondary | Change in tension/anxiety from baseline | At baseline and then at 1, 1.5, 2, 3, 4, 5, and 6 hours after LPS (or saline) administration | Short Form of the Profile of Mood States (POMS-SF) Tension Subscale with higher scores indicating more severe tension/anxiety (range 0-24) |
| Secondary | Change in depressive symptoms from baseline | At baseline and then at 2, 4, and 6 hours after LPS (or saline) administration | Montgomery-Asberg Depression Rating Scale (MADRS): a clinician-rated questionnaire of depressive symptoms with scores ranging from 0 to 60, with higher scores indicating more severe depressive symptoms |
| Secondary | Change in feelings of social disconnection from baseline | At baseline and then at 2, 4, and 6 hours after LPS (or saline) administration | Feelings of Social Disconnection Scale: a self-report questionnaire of feelings of social disconnection with scores ranging from 0 to 28, with higher scores indicating more severe feelings of social disconnection |
| Secondary | Change in fatigue from baseline | At baseline and then at 1, 1.5, 2, 3, 4, 5, and 6 hours after LPS (or saline) administration | Short Form of the Profile of Mood States (POMS-SF) Fatigue Subscale with higher scores indicating more severe fatigue (range 0-20) |
| Secondary | Change in confusion from baseline | At baseline and then at 1, 1.5, 2, 3, 4, 5, and 6 hours after LPS (or saline) administration | Short Form of the Profile of Mood States (POMS) Confusion Subscale with higher scores indicating more severe confusion (range 0-20) |
| Secondary | Change in verbal memory from baseline | At baseline and then 3 hours after LPS (or saline) administration | Verbal memory measured using computerized tests from CNS Vital Signs™ |
| Secondary | Change in visual memory from baseline | At baseline and then 3 hours after LPS (or saline) administration | Visual memory measured using computerized tests from CNS Vital Signs™ |
| Secondary | Change in executive function from baseline | At baseline and then 3 hours after LPS (or saline) administration | Executive function measured using computerized tests from CNS Vital Signs™ |
| Secondary | Change in attention from baseline | At baseline and then 3 hours after LPS (or saline) administration | Attention measured using computerized tests from CNS Vital Signs™ |
| Other | Subjective Sensitivity to Social Rejection | 2 hours after LPS (or saline) administration | Cyberball Social Exclusion Task |
| Other | Negative Bias in Facial Emotion Recognition | 2 hours after LPS (or saline) administration | Emotional Face Recognition Task |
| Other | Reward | 2 hours after LPS (or saline) administration | Reward Learning Task |
| Other | Change in proinflammatory cytokines from baseline | At baseline and then at 1, 1.5, 2, 3, 4, 5, and 6 hours after LPS (or saline) administration | Plasma proinflammatory cytokines (interleukin-1 receptor antagonist, interleukin-6, tumor necrosis factor-α, and soluble tumor necrosis factor receptor) |
| Other | Change in kynurenine Metabolites from baseline | At baseline and then at 1, 1.5, 2, 3, 4, 5, and 6 hours after LPS (or saline) administration | Plasma tryptophan, kynurenine, quinolinic acid, and kynurenic acid |
| Other | Change in gene expression from baseline | At baseline and 30 minutes after LPS (or saline) administration | Genome-wide transcriptional profiling with focus on the percentage increase from baseline to 30 minutes after LPS (or saline) administration in activities of transcription factors related to immune activation, sympathetic activation, and glucocorticoid insensitivity: respectively, nuclear factor kappa-B (NF-kB), cAMP response element-binding protein (CREB), and glucocorticoid receptor (GR). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04309877/registered